Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva/Celltrion's Truxima Is First Biosimilar Rituxan To Reach US Market

Executive Summary

Truxima will launch in the US on 11 November for oncology indications at a 10% discount to the list price of Roche’s innovator Rituxan. The launch marks Teva's first biosimilar launch in the US.

You may also be interested in...



US Biosimilars Strength Rides On The Wings Of Oncology Launches

Herceptin, Avastin and Rituxan biosimilars have achieved notable market penetration, outpacing other biosimilar launches and contributing to lower drug spending, according to a report from Amgen.

Biosimilar Uptake Gains Momentum In The US

Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress. 

Payer, Provider Strategies To Encourage Biosimilar Uptake Gain Momentum

Getting doctors to prescribe lower cost biologics has become less of a challenge as additional products reach the market in the US, according to panelists at the World Biosimilar Congress. 

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC126162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel